Swan Capital’s Pacira BioSciences PCRX Stock Holding History

Swan Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$685	Hold	27	–	–	﹤0.01%	496
2026 Q1	$610	Hold	27	–	–	﹤0.01%	479
2025 Q4	$699	Hold	27	–	–	﹤0.01%	432
2025 Q3	$696	Hold	27	–	–	﹤0.01%	420
2025 Q2	$645	Hold	27	–	–	﹤0.01%	402
2025 Q1	$671	Hold	27	–	–	﹤0.01%	310
2024 Q4	$509	Hold	27	–	–	﹤0.01%	321
2024 Q3	$406	Hold	27	–	–	﹤0.01%	308
2024 Q2	$772	Buy	+27	New	+$768	﹤0.01%	238

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Swan Capital's PCRX Position: Q2 2026 in Review

Swan Capital held its Pacira BioSciences (PCRX) position steady in Q2 2026 at 27 shares worth $685. The position accounts for ﹤0.01% of the portfolio, ranked #496.

Swan Capital first reported a position in PCRX in Q2 2024 and has held it in 9 quarters since. The position peaked at $772 in Q2 2024. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Swan Capital held 27 shares of Pacira BioSciences worth $685 as of Q2 2026.
Swan Capital left its Pacira BioSciences share count unchanged in Q2 2026.
Pacira BioSciences made up ﹤0.01% of Swan Capital's portfolio in Q2 2026, its #496 holding.
Swan Capital first reported a position in Pacira BioSciences in Q2 2024 and has held it in 9 quarters since.
Swan Capital's Pacira BioSciences position peaked at $772 in Q2 2024.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Swan Capital's 13F filing for Q2 2026, filed 13 Aug 2026.